Treatment of Dravet Syndrome

Canadian Journal of Neurological Sciences

Volumn 43, Issue S3, 2016, Pages S13-S18

  Wirrell, Elaine C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiepileptic drug; Dravet syndrome; ketogenic diet; stiripentol

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMIDE; CANNABIDIOL; CARBAMAZEPINE; CLOBAZAM; FENFLURAMINE; LAMOTRIGINE; LEVETIRACETAM; LIDOCAINE; OXCARBAZEPINE; PHENYTOIN; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID;

EPILEPTIC STATE; GLYCEMIC INDEX; HEART VALVE; HOLISTIC CARE; HUMAN; HYPERPOLARIZATION; KETOGENIC DIET; LIVER FUNCTION; MULTICENTER STUDY (TOPIC); NEUROPSYCHOLOGY; OCCUPATIONAL THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SOCIAL WORK; SPEECH THERAPY; THROMBOCYTE COUNT; VAGUS NERVE STIMULATION; EPILEPSIES, MYOCLONIC; PATHOPHYSIOLOGY;

ANTICONVULSANTS; EPILEPSIES, MYOCLONIC; HUMANS;

EID: 84973300193     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2016.249     Document Type: Review

References (44)

1. Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl 2):45-8.
2. Ragona F, Granata T,Dalla Bernardina B,Offredi F, Darra F, Battaglia D, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 2011;52(2):386-92.
3. Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.
4. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet syndrome) [in French]. Arch Pediatr. 2002;9(11):1120-7.
5. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;38(5):508-12.
6. Chipaux M, Villeneuve N, Sabouraud P, Desguerre I, Boddaert N, Depienne C, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure. 2010;19(3):190-4.
7. Ceulemans B. Overall management of patients with Dravet syndrome. Dev Med Child Neurol. 2011;53(Suppl 2):19-23.
8. Mueller A, Boor R, Coppola G, Striano P, Dahlin M, von Stuelpnagel C, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav. 2011;21(3):282-4.
9. Kassai B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2): 343-8.
10. Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P, et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res. 2002;51(1-2):147-53.
11. Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590-4.
12. Striano P, Elefante A, Coppola A, Tortora F, Zara F, Minetti C, et al. Dramatic response to levetiracetam in post-ischaemic Holmes' tremor. J Neurol Neurosurg Psychiatry. 2007;78(4):438-9.
13. Centre for Evidence-Based Medicine. The Oxford 2011 Levels of Evidence. 2011. Available from: http://www.cebm.net/ocebm-levelsof-evidence/.
14. Dressler A, Trimmel-Schwahofer P, Reithofer E, Mühlebner A, Gröppel G, Reiter-Fink E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome: comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81-9.
15. Inoue Y, Ohtsuka Y, STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90-7.
16. Fisher JL. The effects of stiripentol on GABAA receptors. Epilepsia. 2011;52(Suppl 2):76-8.
17. Grosenbaugh DK, Mott DD. Stiripentol in refractory status epilepticus. Epilepsia. 2013;54(Suppl 6):103-5.
18. Fisher JL. The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190-7.
19. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638-42.
20. Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725-31.
21. Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54(9):1595-604.
22. Kouga T, Shimbo H, Iai M, Yamashita S, Ishii A, Ihara Y, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome. Brain Dev. 2015; 37(2):243-9.
23. Kroll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325-9.
24. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250-4.
25. Lotte J, Haberlandt E, Neubauer B, Staudt M, Kluger GJ. Bromide in patients with SCN1A mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17-21.
26. Tanabe T, Awaya Y, Matsuishi T, Iyoda K, Nagai T, Kurihara M, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629-35.
27. Oguni H, Hayashi K, Oguni M, Mukahira A, Uehara T, Fukuyama Y, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia. 1994;35(6):1140-5.
28. Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53(7):1131-9.
29. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extract for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52.
30. Devinsky O, Sullivan J, Friedman D, Thiele E, Marsh E, Laux L, et al. Epidiolex (cannabidiol) in treatment-resistant epilepsy. Available from: http://www.gwpharm.com/uploads/cbdposteraan-r-08apr2015.pdf.
31. Dhamija R, Erickson MK, St Louis EK, Wirrell E, Kotagal S. Sleep abnormalities in children with Dravet syndrome. Pediatr Neurol. 2014;50(5):474-8.
32. Skluzacek JV, Parsy O, Wical B, Camfield P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia. 2011;52(Suppl 2):95-101.
33. Rilstone JJ, Coelho FM, Minassian BA, Andrade DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53(8):1421-8.
34. Rodda JM, Scheffer IE, McMahon JM, Berkovic SF, Graham HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69(7):873-8.
35. Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52(Suppl 2): 79-82.
36. Kang HC, Kim HD, Kim DW. Short-term trial of a liquid ketogenic milk to infants with West syndrome. Brain Dev. 2006;28(1):67.
37. Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011; 52(7):e54-7.
38. Laux L, Blackford R. The ketogenic diet in Dravet syndrome. J Child Neurol. 2013;28(8):1041-4.
39. Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8-14.
40. Rossignol E, Lortie A, Thomas T, Bouthiller A, Scavarda D, Mercier C, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34-7.
41. Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: more to VNS than seizure frequency reduction. Epilepsia. 2009;50(5):1220-8.
42. Spatola M, Jeannet PY, Pollo C, Wider C, Labrum R, Rossetti AO. Effect of vagus nerve stimulation in an adult patient with Dravet syndrome: contribution to sudden unexpected death in epilepsy risk reduction? Eur Neurol. 2013;69(2):119-21.
43. Bremer A, Lossius MI, Nakken KO. Dravet syndrome: considerable delay in making the diagnosis. Acta Neurol Scand. 2012; 125(5):359-62.
44. Orosz I, McCormick D, Zamponi N, Varadkar S, Feucht M, Parain D, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia. 2014;55(10):1576-84.